Search results for "LIPOPROTEIN"

showing 10 items of 982 documents

Alcoholic Beverage and Meal Choices for the Prevention of Noncommunicable Diseases: A Randomized Nutrigenomic Trial

2018

Background. Noncommunicable diseases (NCDs) are the first cause of death worldwide. Mediterranean diet may play a crucial role in the prevention of NCDs, and the presence of wine in this diet could play a positive role on health. Methods. 54 healthy volunteers consumed one of the following beverages: red (RW) or white wine (WW), vodka (VDK), and/or Mediterranean meal (MeDM) and high-fat meal (HFM). Results. OxLDL-C changed significantly between baseline versus HFM, MeDM versus HFM, and HFM versus HFM + RW (p<0.05). Significant upregulation of catalase (CAT) was observed only after RW. Conversely, WW, VDK, RW + MeDM, HF + WW, and HF + VDK determined a significant downregulation of CAT gen…

Male0301 basic medicineAgingGPX1AntioxidantMediterranean dietmedicine.medical_treatmentWineMediterranean030204 cardiovascular system & hematologyDiet Mediterraneanmedicine.disease_causeBiochemistryAntioxidantsNutrigenomicsGlutathione Peroxidase GPX10302 clinical medicineSettore MED/49 - Scienze Tecniche Dietetiche Applicatechemistry.chemical_classificationMeallcsh:CytologyAlcoholic BeveragesGlutathione peroxidaseGeneral MedicineMiddle AgedCatalaseLipoproteins LDLAdolescent; Adult; Aged; Antioxidants; Catalase; Diet High-Fat; Diet Mediterranean; Ethanol; Female; Glutathione Peroxidase; Humans; Lipoproteins LDL; Male; Middle Aged; Noncommunicable Diseases; Nutrigenomics; Oxidative Stress; Superoxide Dismutase; Young Adult; Alcoholic Beverages; Wine; Biochemistry; Aging; Cell BiologyFemaleResearch ArticleAdultmedicine.medical_specialtyAdolescentArticle SubjectLipoproteinsSOD2Diet High-FatLDLYoung Adult03 medical and health sciencesInternal medicinemedicineHumanslcsh:QH573-671Noncommunicable DiseasesAgedGlutathione PeroxidaseEthanolSuperoxide Dismutasebusiness.industryCell BiologyDietHigh-FatOxidative Stress030104 developmental biologyEndocrinologychemistryWhite WinebusinessOxidative stressOxidative Medicine and Cellular Longevity
researchProduct

Garcinoic acid prevents β-amyloid (Aβ) deposition in the mouse brain

2020

Garcinoic acid (GA or δ-T3-13'COOH), is a natural vitamin E metabolite that has preliminarily been identified as a modulator of nuclear receptors involved in β-amyloid (Aβ) metabolism and progression of Alzheimer's disease (AD). In this study, we investigated GA's effects on Aβ oligomer formation and deposition. Specifically, we compared them with those of other vitamin E analogs and the soy isoflavone genistein, a natural agonist of peroxisome proliferator–activated receptor γ (PPARγ) that has therapeutic potential for managing AD. GA significantly reduced Aβ aggregation and accumulation in mouse cortical astrocytes. Similarly to genistein, GA up-regulated PPARγ expression and apolipoprote…

Male0301 basic medicineApolipoprotein EBiologiamedicine.medical_treatmentMetaboliteGenisteinFisiologiavitamin EPharmacologyProtein Aggregation PathologicalBiochemistry)protein aggregationgenisteinMiceProtein Aggregates03 medical and health scienceschemistry.chemical_compoundperoxisome proliferator-activated receptor gamma (PPARγ)neurodegenerative diseaseNeurobiologygarcinoic acidmedicineAnimalsBenzopyranstocotrienolReceptorMolecular BiologyPregnane X receptorAmyloid beta-Peptidespregnane X receptor (PXR)peroxisome proliferator-activated receptor (PPAR)030102 biochemistry & molecular biologyVitamin EBrainCell BiologyAlzheimer's diseasetocopherol030104 developmental biologyNuclear receptorchemistryperoxisome proliferator-activated receptor gamma (PPAR gamma)amyloid-beta (AB)apolipoprotein E (ApoETocotrienolAlzheimer diseaseapolipoprotein E (ApoE)
researchProduct

Associations of Genetic Susceptibility to Alzheimer’s Disease with Adiposity and Cardiometabolic Risk Factors among Children in a 2-Year Follow-up St…

2018

We investigated the associations of genetic risk score (GRS) for Alzheimer's disease and apolipoprotein E (APOE) ɛ variant with cardiometabolic risk factors during 2-year follow-up in children and whether body fat percentage (BF%) modify these associations. A population-based sample of 469 children (246 boys, 223 girls) at baseline and 398 children (201 boys, 197 girls) at 2-year follow-up participated in the study. Genotyping was performed using the Illumina Custom Infinium CardioMetabo BeadChip and the Illumina Infinium HumanCoreExome BeadChip. The GRS was calculated using information on nine independent gene variants available in our genomic data. We assessed BF%, waist circumference, in…

Male0301 basic medicineApolipoprotein Emedicine.medical_specialtyWaistPopulationBody fat percentage03 medical and health scienceschemistry.chemical_compoundApolipoproteins E0302 clinical medicineInsulin resistanceAlzheimer DiseaseRisk FactorsInternal medicineHumansMedicineGenetic Predisposition to DiseaseLongitudinal StudiesChildeducationAdiposityeducation.field_of_studybusiness.industryCholesterolGeneral NeuroscienceBody WeightGeneral Medicinemedicine.diseasePsychiatry and Mental healthClinical PsychologyCholesterol030104 developmental biologychemistryHomeostatic model assessmentFemaleInsulin ResistanceGeriatrics and GerontologyMetabolic syndromebusiness030217 neurology & neurosurgeryGenome-Wide Association StudyJournal of Alzheimer's Disease
researchProduct

Elevated levels of 2-arachidonoylglycerol promote atherogenesis in ApoE-/- mice.

2018

Background The endocannabinoid (eCB) 2-arachidonoylglycerol (2-AG) is a known modulator of inflammation and ligand to both, pro-inflammatory cannabinoid receptor 1 (CB1) and anti-inflammatory CB2. While the role of both receptors in atherogenesis has been studied extensively, the significance of 2-AG for atherogenesis is less well characterized. Methods The impact of 2-AG on atherogenesis was studied in two treatment groups of ApoE-/- mice. One group received the monoacylglycerol lipase (MAGL)-inhibitor JZL184 [5 mg/kg i.p.], which impairs 2-AG degradation and thus causes elevated 2-AG levels, the other group received vehicle for four weeks. Simultaneously, both groups were fed a high-chole…

Male0301 basic medicineCCR1Chemokinelcsh:MedicineSmooth Muscle Cells030204 cardiovascular system & hematologyPathology and Laboratory MedicineBiochemistryMonocytesWhite Blood CellsMicechemistry.chemical_compoundChemokine receptorSpectrum Analysis Techniques0302 clinical medicinePiperidinesAnimal CellsCell MovementMedicine and Health SciencesReceptorlcsh:ScienceImmune ResponseJZL184MultidisciplinarybiologyNeurochemistryFlow CytometryLipidsCholesterolSpectrophotometryCytophotometryCellular TypesNeurochemicalsAnatomymedicine.symptomResearch Articlemedicine.medical_specialtyImmune CellsImmunologyMuscle TissueAntigens Differentiation MyelomonocyticInflammationArachidonic AcidsResearch and Analysis MethodsDiet High-FatCell LineGlycerides03 medical and health sciencesSigns and SymptomsApolipoproteins EDiagnostic MedicineAntigens CDInternal medicinemedicineAnimalsOil Red OBenzodioxolesInflammationMuscle CellsBlood CellsMacrophageslcsh:RBiology and Life SciencesCell BiologyAtherosclerosisMonoacylglycerol lipaseBiological Tissue030104 developmental biologyEndocrinologychemistrybiology.proteinlcsh:QEndocannabinoidsNeurosciencePLoS ONE
researchProduct

Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?

2016

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) regulates the expression of low-density lipoprotein (LDL)-receptors, through reducing their recycling by binding to the receptor along with LDL and targeting it for lysosomal destruction. PCSK9 also enhances the degradation of very-low-density-lipoprotein receptor (VLDLR) and lipoprotein receptor-related protein 1 (LRP-1) in a LDL-receptor independent manner. This role in lipid homeostasis presents PCSK9 as an attractive target for the therapeutic management of familial hypercholesterolemia as well as other refractory dyslipidaemias. However, PCSK9 mediates multifarious functions independent of its role in lipid homeostasis, which can be…

Male0301 basic medicineCell signalingHIPERCOLESTEROLEMIALow-density lipoprotein receptor gene familyHypercholesterolemiaMice TransgenicFamilial hypercholesterolemiaBiologyAntiviral AgentsPermeabilityMice03 medical and health sciencesAlzheimer DiseasemedicineAnimalsHomeostasisHumansGlucose homeostasisRNA Small InterferingEpithelial Sodium ChannelsGlycoproteinsNeuronsPCSK9PCSK9 InhibitorsAntibodies MonoclonalCell DifferentiationOligonucleotides Antisensemedicine.diseaseProprotein convertaseLipidsCircadian RhythmLiver RegenerationCell biology030104 developmental biologyReceptors LDLBiochemistryLDL receptorKexinFemalelipids (amino acids peptides and proteins)CRISPR-Cas SystemsProprotein Convertase 9Cardiology and Cardiovascular MedicineAtherosclerosis
researchProduct

Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hy…

2018

International audience; Background and Aim: Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays a key role in atherosclerosis development. It is considered a marker of increased risk of cardiovascular disease (CVD) and plaque vulnerability. Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated plasma levels of low-density lipoprotein cholesterol and a higher prevalence of early CVD. Our aim was to evaluate the differences in Lp-PLA2 activity in a population of hypercholesterolemic patients with and without definite FH.Methods and Results: Hypercholesterolemic patients were consecutively recruited. Definite FH was defined according to Dutch Lipid Clinic Netwo…

Male0301 basic medicineEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Low density lipoproteinDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologyGastroenterologychemistry.chemical_compound0302 clinical medicineVascular inflammationeducation.field_of_studyNutrition and Dieteticsmedicine.diagnostic_testGenetic disorderMiddle Aged[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismCardiovascular diseaseLipidsUp-Regulation3. Good healthPhenotypeLow-density lipoproteinApolipoprotein B-100Femalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyStatin treatmentHypercholesterolemiaFamilial hypercholesterolemiaPopulationPhysical examinationHyperlipoproteinemia Type II03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansLipoprotein-associated phospholipase A2Plaque vulnerabilityeducationAgedApolipoprotein A-Ibusiness.industryCholesterol HDLCholesterol LDLStatin treatmentAtherosclerosisCardiovascular riskmedicine.diseaseCross-Sectional Studies030104 developmental biologychemistry1-Alkyl-2-acetylglycerophosphocholine EsteraseHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkersLipoproteinNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Microsomal triglyceride transfer protein gene mutations in Turkish children: A novel mutation and clinical follow up.

2016

Abetalipoproteinemia (ABL; OMIM 200100) is a rare autosomal recessive disease that affects the absorption of dietary fats and fat soluble vitamins. Here, we describe the clinical and genetic characteristics of three patients with ABL. Two patients (patients 1 and 2) who were carriers of the c.398-399delAA mutation (previously known mutation) had developmental delay and hepatic steatosis developed at the age of five in patient 1. Patient 3 was the carrier of a novel mutation (g.10886-10902delAAGgtaagtttgtgttg in intron 3 and c.506A>T exon 5) in microsomal triglyceride transfer protein (MTP) gene and had hepatic steatosis.

Male0301 basic medicineHeterozygotemedicine.medical_specialtySettore MED/09 - Medicina InternaTurkeyDevelopmental delayDevelopmental DisabilitiesTurkish030204 cardiovascular system & hematologyHepatic steatosimedicine.disease_causeMicrosomal triglyceride transfer protein03 medical and health sciencesExon0302 clinical medicineInternal medicineHumansMedicineGeneGenetic Association StudiesGeneticsMutationABLbiologyAbetalipoproteinemiaDevelopmental delayHepatic steatosisMicrosomal triglyceride transfer proteinTurkishbusiness.industryIntronGastroenterologyInfantAbetalipoproteinemiaMicrosomal triglyceride transfer proteinmedicine.diseaseIntronsAbetalipoproteinemiaFatty Liver030104 developmental biologyEndocrinologyMutationbiology.proteinFemaleSteatosisCarrier ProteinsbusinessFollow-Up Studies
researchProduct

Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis

2019

Antiphospholipid antibodies (aPLs) with complex lipid and/or protein reactivities cause complement-dependent thrombosis and pregnancy complications. Although cross-reactivities with coagulation regulatory proteins contribute to the risk for developing thrombosis in patients with antiphospholipid syndrome, the majority of pathogenic aPLs retain reactivity with membrane lipid components and rapidly induce reactive oxygen species-dependent proinflammatory signaling and tissue factor (TF) procoagulant activation. Here, we show that lipid-reactive aPLs activate a common species-conserved TF signaling pathway. aPLs dissociate an inhibited TF coagulation initiation complex on the cell surface of m…

Male0301 basic medicineLipoproteinsImmunologyPlenary Paper030204 cardiovascular system & hematologyBiochemistryMonocytesThromboplastinProinflammatory cytokine03 medical and health sciencesTissue factor0302 clinical medicineTissue factor pathway inhibitorThrombinimmune system diseasesmedicineAnimalsHumansThromboplastinBlood CoagulationneoplasmsCells CulturedNADPH oxidasebiologyChemistryThrombosisCell BiologyHematologyComplement systemMice Inbred C57BL030104 developmental biologyAntibodies Antiphospholipidbiology.proteinCancer researchFemaleSignal transductionSignal Transductionmedicine.drugBlood
researchProduct

Mediterranean Diet and atherothrombosis biomarkers: a randomized controlled trial

2020

Scope To assess whether following a Mediterranean diet (MedDiet) improves atherothrombosis biomarkers in high cardiovascular risk individuals. Methods and results In 358 random volunteers from the PREvención con DIeta MEDiterránea trial, the 1‐year effects on atherothrombosis markers of an intervention with MedDiet, enriched with virgin olive oil (MedDiet‐VOO; n = 120) or nuts (MedDiet‐Nuts; n = 119) versus a low‐fat control diet (n = 119), and whether large increments in MedDiet adherence (≥3 score points, versus compliance decreases) and intake changes in key food items are associated with 1‐year differences in biomarkers. Differences are observed between 1‐year changes in the MedDiet‐VOO…

Male0301 basic medicineMediterranean dietProcessed meat intakeAtherothrombosisDiet MediterraneanFibrinogenGastroenterologyCardiovascular riskslaw.inventionFood groupEatingchemistry.chemical_compoundClinical trialsRandomized controlled triallawPlateletNitriteAged 80 and overchemistry.chemical_classificationAntithrombinMiddle AgedThrombosisCardiovascular diseasesBiomarker (medicine)FemaleDietaLipoproteins HDLBiotechnologymedicine.drugcardiovascular riskmedicine.medical_specialty03 medical and health sciencesFatty fishMediterranean cookingThrombinMediterranean dietInternal medicineCuina mediterràniamedicineHumansOlive OilAged030109 nutrition & dieteticsMalalties cardiovascularsbusiness.industryFatty acidThrombosisAtherosclerosismedicine.diseaseConfidence intervalDietCross-Sectional Studies030104 developmental biologyEndocrinologychemistryalpha 1-AntitrypsinbusinessBiomarkersFood Science
researchProduct

Homozygous Familial Hypercholesterolemia in Spain Prevalence and Phenotype-Genotype Relationship

2016

Background— Homozygous familial hypercholesterolemia (HoFH) is a rare disease characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) and extremely high risk of premature atherosclerotic cardiovascular disease. HoFH is caused by mutations in several genes, including LDL receptor ( LDLR ), apolipoprotein B ( APOB ), proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), and LDL protein receptor adaptor 1 ( LDLRAP1 ). No epidemiological studies have assessed HoFH prevalence or the clinical and molecular characteristics of this condition. Here, we aimed to characterize HoFH in Spain. Methods and Results— Data were collected from the Spanish Dyslipidemia Regist…

Male0301 basic medicineOncologyLdl receptor geneApolipoprotein BLipid-lowering therapyFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosity0302 clinical medicineAutosomal-dominant hypercholesterolemiaRisk FactorsEpidemiologyPrevalenceDiseaseRegistriesGenetics (clinical)Molecular EpidemiologybiologyhypercholesterolemiaHomozygoteDouble-blindMiddle AgedPhenotypeCardiovascular DiseasesApolipoprotein B-100allelesFemalelipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineMutationsAdultGenetic MarkersHeterozygotemedicine.medical_specialtyInhibitorAdolescentPlacebo-controlled trialHyperlipoproteinemia Type IIlipidsYoung Adult03 medical and health sciencesInternal medicineGeneticsmedicineHumansGenetic Predisposition to DiseaseAlleleAdaptor Proteins Signal TransducingRecessive hypercholesterolemiaPCSK9registriesCholesterol LDLApolipoprotein-bmedicine.disease030104 developmental biologyEndocrinologyReceptors LDLSpainMutationLDL receptorbiology.proteinmutationDyslipidemia
researchProduct